UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients.

Autor: Li A; Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London., Erridge S; Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London.; Sapphire Medical Clinics., Holvey C; Sapphire Medical Clinics., Coomber R; Sapphire Medical Clinics.; St. George's Hospital NHS Trust., Barros D; Sapphire Medical Clinics., Bhoskar U; Sapphire Medical Clinics., Crews M; Sapphire Medical Clinics., Donnelly L; Sapphire Medical Clinics., Imran M; Sapphire Medical Clinics., Korb L; Sapphire Medical Clinics.; North London Mental Health Partnership., Mwimba G; Sapphire Medical Clinics., Sachdeva-Mohan S; Sapphire Medical Clinics., Rucker JJ; Department of Psychological Medicine, Kings College London.; South London & Maudsley NHS Foundation Trust, London, UK., Sodergren MH; Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London.; Sapphire Medical Clinics.
Jazyk: angličtina
Zdroj: International clinical psychopharmacology [Int Clin Psychopharmacol] 2024 Nov 01; Vol. 39 (6), pp. 350-360. Date of Electronic Publication: 2024 Feb 02.
DOI: 10.1097/YIC.0000000000000536
Abstrakt: This study aims to analyze changes in health-related quality of life (HRQoL) and safety in patients with generalized anxiety disorder (GAD) prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). Patients prescribed Adven CBMPs (Curaleaf International, UK) for GAD were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in patient-reported outcome measures (PROMs) from baseline up to 12 months, including GAD-7, Single-Item Sleep Quality Scale (SQS), and EQ-5D-5L. Adverse events were recorded using CTCAE version 4.0. A total of 120 patients were identified for inclusion, of which 38 (31.67%), 52 (43.33%), and 30 (25.00%) were prescribed oils, dried flower, and both formulations of CBMP. Associated improvements in GAD-7, SQS, and EQ-5D-5L at 1, 3, 6, and 12 months were observed compared to baseline ( P  < 0.010). There were 24 (20.00%) patients who reported 442 (368.33%) adverse events, most of which were mild (n = 184, 41.63%) and moderate (n = 197, 44.57%). This study reports an association between initiation of a homogeneous CBMP therapy and improvements in anxiety severity and HRQoL in individuals with GAD. Moreover, therapy was well-tolerated at 12 months follow-up. Further investigation through randomized controlled trials will ultimately be required to determine causation.
(Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze: MEDLINE
Externí odkaz: